Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - ImmunoCellular Therapeutics, Ltd. | imuc-ex312_6.htm |
| EX-31.1 - EX-31.1 - ImmunoCellular Therapeutics, Ltd. | imuc-ex311_11.htm |
| EX-32.2 - EX-32.2 - ImmunoCellular Therapeutics, Ltd. | imuc-ex322_10.htm |
| EX-10.1 - EX-10.1 - ImmunoCellular Therapeutics, Ltd. | imuc-ex101_127.htm |
| EX-10.3 - EX-10.3 - ImmunoCellular Therapeutics, Ltd. | imuc-ex103_126.htm |
| EX-10.2 - EX-10.2 - ImmunoCellular Therapeutics, Ltd. | imuc-ex102_125.htm |
| 10-Q - 10-Q - ImmunoCellular Therapeutics, Ltd. | imuc-10q_20150630.htm |
Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:
|
1. |
The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2015 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
|
2. |
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: August 7, 2015 |
By: |
/s/ Andrew Gengos |
|
|
|
|
Name: |
Andrew Gengos |
|
|
|
Title: |
President and Chief Executive Officer |